Medical Director of Pennsylvania's Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies' Medical and Scientific Advisory Board and Incorporates CyPath Lung into Medical Practice
SAN ANTONIO, Texas (Feb. 6, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer including CyPath Lung, today announced that Sandeep Bansal, M.D., Medical Director of Lung Innovations Network, has joined the Company's Medical and Scientific Advisory Board to provide expert advice and counsel on bioAffinity Technology products and research.
Lung Innovations Network, a patient-centered practice that offers comprehensive lung care to over 10,000 patients in central and western Pennsylvania, will incorporate CyPath Lung into its practice to aid in the detection of early-stage lung cancer.
"As a clinician, I see hundreds of patients a year who can directly benefit from CyPath Lung, bioAffinity's patient-friendly, noninvasive test for lung cancer. As a researcher, I am excited about the Company's ongoing studies to advance CyPath Lung, as well as noninvasive tests for other lung diseases," Dr. Bansal said. "I look forward to contributing to bioAffinity's innovative approach to lung health by working with the Company's science team and the esteemed physicians and researchers who sit on its advisory board."
Dr. Bansal has extensive experience in minimally invasive pulmonary procedures including navigational and robotic bronchoscopy, endobronchial ultrasound and chest sonography, argon plasma coagulation, cryotherapy, airway stenting, bronchoscopic lung volume reduction and indwelling pleural catheters. A principal investigator of multiple clinical research trials and a journal reviewer for several medical journals, he has been instrumental in developing a comprehensive lung center that allows a rapid assessment and management of healthcare needs based on the population characteristics and available resources. The model has been very successful in bringing advanced pulmonary services, including the latest technology and population health services, including a robust lung cancer screening program, to support the region's clinical needs.
"Dr. Bansal is a highly regarded clinician and researcher who will be a strong addition to our stellar Medical and Scientific Advisory Board. His demonstrated commitment to saving lives and improving patients' quality of life through innovative therapies and his prodigious research are truly impressive," bioAffinity Technologies President and CEO Maria Zannes said. "The caliber of our Advisory Board is a testament to the commitment each physician has placed on bringing breakthrough technology to market in the battle against lung cancer and other diseases of the lung."
賓夕法尼亞州肺部創新網絡和賓夕法尼亞高地醫療保健公司肺部中心醫學總監，醫學博士桑迪普·班薩爾加入了BioAffinity Technologies的醫學和科學顧問委員會，並將Cypath Lung納入醫療實踐
德克薩斯州聖安東尼奧（2024 年 2 月 6 日）— bioAffinity Technologies, Inc.（納斯達克股票代碼：BIAF；BIAFW）是一家專注於通過無創檢測來檢測包括CyPath Lung在內的早期癌症的生物技術公司，今天宣佈，醫學總監桑迪普·班薩爾醫學博士 肺部創新網絡，已加入該公司 醫學和科學顧問委員會 就 BioAffinity Technology 產品和研究提供專家建議和諮詢。
肺部創新網絡是一家以患者爲中心的診所，爲賓夕法尼亞州中部和西部的10,000多名患者提供全面的肺部護理，它將把CyPath Lung納入其實踐中，以幫助發現早期肺癌。
“作爲臨床醫生，我每年爲數百名患者看病，他們可以直接從CyPath Lung中受益，這是BioAffinity對患者友好、無創的肺癌檢測。作爲一名研究人員，我對該公司正在進行的推進CyPath Lung的研究以及針對其他肺部疾病的無創測試感到興奮，” 班薩爾博士說。“我期待與BioAffinity的科學團隊以及顧問委員會中受人尊敬的醫生和研究人員合作，爲BioAffinity的肺部健康創新方法做出貢獻。”
Bansal博士在微創肺部手術方面擁有豐富的經驗，包括導航和機器人支氣管鏡檢查、支氣管內超聲和胸部超聲檢查、氬血漿凝固、冷凍療法、氣道支架置入、支氣管鏡肺容量減少和留置胸膜導管。作爲多項臨床研究試驗的首席研究員和多份醫學期刊的期刊審稿人，他在開發綜合肺部中心方面發揮了重要作用，該中心允許根據人群特徵和可用資源快速評估和管理醫療需求。該模式非常成功地提供了先進的肺部服務，包括最新的技術和人口健康服務，包括強大的肺癌篩查計劃，以支持該地區的臨床需求。
“班薩爾博士是一位備受推崇的臨床醫生和研究人員，他將成爲我們出色的醫學和科學顧問委員會的有力補充。BioAffinity Technologies總裁兼首席執行官瑪麗亞·贊內斯說，他表現出的通過創新療法挽救生命和改善患者生活質量的承諾以及他的出色研究確實令人印象深刻。“我們顧問委員會的才幹證明了每位醫生都致力於將突破性技術推向市場，以對抗肺癌和其他肺部疾病。”
